Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 10 |
| List of Tables | 6 | 4 |
| List of Figures | 10 | 3 |
| Respiratory Disorders Therapeutics Market to 2017 - Introduction | 13 | 2 |
| GBI Research Report Guidance | 14 | 1 |
| Respiratory Disorders Therapeutics Market to 2017 - Market Overview | 15 | 10 |
| Introduction | 15 | 1 |
| Revenue Forecasts for Respiratory Disorders Therapeutics Market | 15 | 1 |
| Revenues | 15 | 2 |
| Revenue Share by Geography | 17 | 2 |
| Global Generic Share | 19 | 1 |
| Annual Cost of Therapy | 20 | 1 |
| Treatment Usage Patterns | 21 | 2 |
| Drivers and Barriers for Respiratory Disorders Therapeutics Market | 23 | 1 |
| Drivers for Respiratory Disorders | 23 | 1 |
| Increase in Smoking Population | 23 | 1 |
| Depleting Environmental Conditions | 23 | 1 |
| Increase in Awareness Levels of Disease Progression and Etiology | 24 | 1 |
| Stable Increase in the Number of Incidences of Respiratory Disorders | 24 | 1 |
| Barriers for Respiratory Disorders | 24 | 1 |
| Patent Expirations and Entry of Generics Pose a Serious Problem for Primary Manufacturers | 24 | 1 |
| Reimbursement Restrictions on Drug Classes For Certain Respiratory Disorder Drug Classes Restricts the Market Growth | 24 | 1 |
| Respiratory Disorders Therapeutics Market to 2017 - Geographical Landscape | 25 | 14 |
| The US | 25 | 1 |
| Revenue | 25 | 1 |
| Annual Cost of Therapy | 26 | 1 |
| Treatment Usage Pattern | 27 | 2 |
| Top Five Countries of Europe | 29 | 1 |
| Revenue | 29 | 1 |
| Revenue Share by Country | 30 | 2 |
| Annual Cost of Therapy | 32 | 1 |
| Treatment Usage Pattern | 33 | 2 |
| Japan | 35 | 1 |
| Revenue | 35 | 1 |
| Annual Cost of Therapy | 36 | 1 |
| Treatment Usage Pattern | 37 | 2 |
| Respiratory Disorders Therapeutics Market to 2017 - Therapeutic Landscape | 39 | 70 |
| Asthma | 39 | 1 |
| Introduction | 39 | 1 |
| Revenue | 39 | 2 |
| Geographical Segmentation | 41 | 2 |
| Generic Share | 43 | 1 |
| Annual Cost of Therapy | 44 | 1 |
| Treatment Usage Patterns | 45 | 2 |
| Treatment Flow Algorithm | 47 | 1 |
| Drivers and Barriers for Asthma | 48 | 1 |
| Drivers for Asthma | 48 | 1 |
| Barriers for Asthma | 49 | 1 |
| COPD | 50 | 1 |
| Introduction | 50 | 1 |
| Revenue | 50 | 2 |
| Geographical Segmentation | 52 | 2 |
| Generic Share | 54 | 1 |
| Annual Cost of Therapy | 55 | 1 |
| Treatment Usage Patterns | 56 | 2 |
| Treatment Flow Algorithm | 58 | 1 |
| Drivers and Barriers for COPD | 59 | 1 |
| Drivers for COPD | 59 | 1 |
| Barriers for COPD | 59 | 1 |
| Pulmonary Arterial Hypertension | 60 | 1 |
| Introduction | 60 | 1 |
| Pulmonary Arterial Hypertension | 60 | 1 |
| Pulmonary Venous Hypertension | 60 | 1 |
| Pulmonary Hypertension Associated With Hypoxemia | 61 | 1 |
| Pulmonary Hypertension Due To Chronic Thrombotic and/or Embolic Disease | 61 | 1 |
| Miscellaneous | 61 | 1 |
| Revenue | 62 | 1 |
| Geographical Segmentation | 63 | 2 |
| Generic Share | 65 | 1 |
| Annual Cost of Therapy | 66 | 1 |
| Treatment Usage Patterns | 67 | 2 |
| Treatment Flow Algorithm | 69 | 1 |
| Drivers and Barriers for Pulmonary Arterial Hypertension | 70 | 1 |
| Drivers for Pulmonary Arterial Hypertension | 70 | 1 |
| Barriers for Pulmonary Arterial Hypertension | 70 | 1 |
| Cystic Fibrosis | 71 | 1 |
| Introduction | 71 | 1 |
| Revenue | 71 | 2 |
| Geographical Segmentation | 73 | 2 |
| Generic Share | 75 | 1 |
| Annual Cost of Therapy | 76 | 1 |
| Treatment Usage Patterns | 77 | 2 |
| Treatment Flow Algorithm | 79 | 1 |
| Drivers and Barriers for Cystic Fibrosis | 80 | 1 |
| Drivers for Cystic Fibrosis | 80 | 1 |
| Barriers for Cystic Fibrosis | 80 | 1 |
| Allergic Rhinitis | 81 | 1 |
| Introduction | 81 | 1 |
| Revenue | 81 | 2 |
| Geographical Segmentation | 83 | 2 |
| Generic Share | 85 | 1 |
| Annual Cost of Therapy | 86 | 1 |
| Treatment Usage Patterns | 87 | 1 |
| Treatment Flow Algorithm | 88 | 1 |
| Drivers and Barriers for Allergic Rhinitis | 89 | 1 |
| Drivers for Allergic Rhinitis | 89 | 1 |
| Barriers for Allergic Rhinitis | 89 | 1 |
| Idiopathic Pulmonary Fibrosis | 90 | 1 |
| Introduction | 90 | 1 |
| Revenue | 90 | 1 |
| Geographical Segmentation | 91 | 2 |
| Generic Share | 93 | 1 |
| Annual Cost of Therapy | 94 | 1 |
| Treatment Usage Patterns | 95 | 2 |
| Treatment Flow Algorithm | 97 | 1 |
| Drivers and Barriers for Idiopathic Pulmonary Fibrosis | 98 | 1 |
| Drivers for Idiopathic Pulmonary Fibrosis | 98 | 1 |
| Barrier for Idiopathic Pulmonary Fibrosis | 98 | 1 |
| Bronchitis | 99 | 1 |
| Introduction | 99 | 1 |
| Revenue | 99 | 2 |
| Geographical Segmentation | 101 | 2 |
| Generic Share | 103 | 1 |
| Annual Cost of Therapy | 104 | 1 |
| Treatment Usage Patterns | 105 | 2 |
| Treatment Flow Algorithm | 107 | 1 |
| Drivers and Barriers for Bronchitis | 108 | 1 |
| Drivers for Bronchitis | 108 | 1 |
| Barriers for Bronchitis | 108 | 1 |
| Respiratory Disorders Therapeutics Market to 2017 - Product Pipeline Analysis | 109 | 28 |
| Introduction | 109 | 2 |
| Research and Development Pipeline - Asthma | 111 | 6 |
| Research and Development Pipeline - COPD | 117 | 4 |
| Research and Development Pipeline - Pulmonary Arterial Hypertension | 121 | 2 |
| Research and Development Pipeline - Cystic Fibrosis | 123 | 2 |
| Research and Development Pipeline - Allergic Rhinitis | 125 | 3 |
| Research and Development Pipeline - Idiopathic Pulmonary Fibrosis | 128 | 2 |
| Research and Development Pipeline - Bronchitis | 130 | 1 |
| Profiles of Promising Drugs in the Respiratory Disorders Therapeutics Market | 131 | 1 |
| Bilastine | 131 | 1 |
| Overview | 131 | 1 |
| Efficacy | 131 | 1 |
| Safety | 131 | 1 |
| Clinical Study Details | 131 | 1 |
| Sublivac (Extracts of Allergens) | 131 | 1 |
| Overview | 131 | 1 |
| Efficacy | 132 | 1 |
| Safety | 132 | 1 |
| Clinical Study Details | 132 | 1 |
| Duonase (Azelastine + Fluticasone) | 132 | 1 |
| Overview | 132 | 1 |
| Efficacy | 132 | 1 |
| Safety | 132 | 1 |
| Clinical Study Details | 132 | 1 |
| Riociguat | 133 | 1 |
| Introduction | 133 | 1 |
| Efficacy | 133 | 1 |
| Safety | 133 | 1 |
| Clinical Study Details | 133 | 1 |
| VX-770 | 133 | 1 |
| Introduction | 133 | 1 |
| Efficacy | 133 | 1 |
| Safety | 134 | 1 |
| Clinical Study Details | 134 | 1 |
| Indacaterol | 134 | 1 |
| Introduction | 134 | 1 |
| Efficacy | 134 | 1 |
| Safety | 135 | 1 |
| Clinical Trial Details | 135 | 1 |
| NVA237 (Glycopyrronium Bromide) | 135 | 1 |
| Overview | 135 | 1 |
| Efficacy | 135 | 1 |
| Safety | 135 | 1 |
| Clinical Study Details | 135 | 1 |
| Aclidinium Bromide | 136 | 1 |
| Overview | 136 | 1 |
| Efficacy | 136 | 1 |
| Safety | 136 | 1 |
| Clinical Study Details | 136 | 1 |
| Respiratory Disorders Therapeutics Market to 2017 - Competitive Landscape | 137 | 18 |
| Market Share Analysis: Respiratory Disorders Market | 137 | 1 |
| Drug Profile of Major Marketed Products | 138 | 1 |
| Advair Diskus (fluticasone propionate and salmeterol inhalation powder) | 138 | 1 |
| Overview | 138 | 1 |
| Efficacy | 138 | 1 |
| Safety | 138 | 1 |
| Clinical Study Details | 139 | 1 |
| Symbicort (budesonide/formoterol fumarate dihydrate inhalation aerosol) | 140 | 1 |
| Overview | 140 | 1 |
| Efficacy | 140 | 1 |
| Safety | 140 | 1 |
| Clinical Study Details | 140 | 1 |
| Singulair (montekeulast sodium) | 141 | 1 |
| Overview | 141 | 1 |
| Efficacy | 141 | 1 |
| Safety | 141 | 1 |
| Clinical Study Details | 141 | 1 |
| Tracleer | 142 | 1 |
| Overview | 142 | 1 |
| Efficacy | 142 | 1 |
| Safety Profile | 142 | 1 |
| Clinical Study Details | 143 | 1 |
| Nasonex (mometasone furoate monohydrate) | 143 | 1 |
| Overview | 143 | 1 |
| Efficacy | 143 | 1 |
| Safety | 143 | 1 |
| Clinical Study Details | 144 | 1 |
| Competitive Profiling | 145 | 1 |
| AstraZeneca | 145 | 1 |
| Overview | 145 | 1 |
| SWOT Analysis | 146 | 1 |
| GlaxoSmithKline | 147 | 1 |
| Overview | 147 | 1 |
| SWOT Analysis | 148 | 1 |
| Merck &Co., Inc. | 149 | 1 |
| Overview | 149 | 1 |
| SWOT Analysis | 150 | 1 |
| Actelion | 151 | 1 |
| Overview | 151 | 1 |
| SWOT Analysis | 152 | 1 |
| Novartis | 153 | 1 |
| Overview | 153 | 1 |
| SWOT Analysis | 154 | 1 |
| Respiratory Disorders Therapeutics Market to 2017 - M&A Landscape | 155 | 10 |
| M&A Landscape | 155 | 1 |
| M&A Deals by Year | 155 | 1 |
| M&A Deals by Value | 156 | 1 |
| M&A Deals by Value ($) | 156 | 1 |
| M&A Deals by Geography | 157 | 1 |
| M&A Deals by Deal Type | 158 | 1 |
| M&A Deals by Deal Sub-Type | 159 | 1 |
| R&D Licensing Agreements | 160 | 1 |
| Deals by Year | 160 | 1 |
| Deals by Geography | 161 | 1 |
| Deals by Value ($) | 162 | 1 |
| Licensing Agreements by Value ($) | 162 | 1 |
| Co-Development Agreements | 163 | 1 |
| Deals by Year | 163 | 1 |
| Deals by Geography | 164 | 1 |
| Respiratory Disorders Therapeutics Market to 2017 - Appendix | 165 | 7 |
| Market Definitions | 165 | 1 |
| Abbreviations | 165 | 1 |
| Research Methodology | 166 | 5 |
| Coverage | 166 | 1 |
| Secondary Research | 166 | 1 |
| Primary Research | 167 | 1 |
| Section Wise Methodology | 167 | 1 |
| Therapeutic Landscape | 167 | 3 |
| Geographical Landscape | 170 | 1 |
| Pipeline Analysis | 170 | 1 |
| Competitive Landscape | 170 | 1 |
| Expert Panel Validation | 170 | 1 |
| Contact Us | 170 | 1 |
| Disclaimer | 171 | 1 |
| Sources | 171 | 1 |